glp 1 lily Eli Lilly's New Oral GLP-1 Orforglipron Beats Semaglutide In Diabetes Trials; FDA Filing Near FDA approves Lilly's Foundayo™ (orforglipron),

Proteomics 11 , M112.017988 (2012)

(II) Elevated SCFA levels act as signaling molecules and potent epigenetic modifiersfunctioning as HDACi and EZH2i inhibitorsto suppress profibrotic gene expression and stabilize inhibitory regulators such as Smad7

Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19

Comparison with previous studies The SUSTAIN 9 (Semaglutide once weekly as add-on to SGLT-2i therapy in T2DM) and SURPASS-1 (Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist Tirzepatide in patients with type 2 diabetes) trials demonstrated that both SGLT2i and GLP-1RAs reduced HbA1c and body weight levels compared with placebo in patients with a history of medical treatment for diabetes ( Safety outcomes The SUSTAIN-9 trial demonstrated an association between SGLT2i use and genital and urinary tract infections ( Discrepancies in the SGLT2i or GLP-1RA type and dosage across studies may have influenced the results